Avalyn Pharma Inc.
Avalyn Pharma is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. It develops inhaled medicines for people with rare respiratory conditions, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline includes AP01 and AP02, inhaled versions of pirfenidone and nintedanib for progressive and idiopathic pulmonary fibrosis. AP03 combines both medicines in a fixed-dose inhaled treatment.
No SEC Form 4 filings for $AVLN in the last 30 days.
See all $AVLN insider activity →Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers Presented new AP01 data at ERS Congress and published detailed results from
Avalyn Pharma Inc. stock options are locked up until 27-OCT-2026. Directors, officers, and major holders agreed not to sell or transfer shares for 180 days post-prospectus. The company focuses on inhaled therapies for pulmonary fibrosis, with clinical trials ongoing for AP01, AP02, and AP03.
Raymond James initiated coverage on Avalyn Pharma (NASDAQ:AVLN) with an outperform rating and a $60 price target, implying over 118% upside. The company is developing inhaled antifibrotics for pulmonary fibrosis, with two Phase 2 assets. Avalyn's market cap is $1.22B, and it has a strong balance sheet. Raymond James expects catalysts in late 2027, while InvestingPro suggests the stock may be overvalued.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AVLN (Avalyn Pharma Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AVLN coverage spans corporate actions, earnings and financial news.
The cash runway and new trial suggest near‑term funding stability and potential upside if early data are positive.
The lock‑up limits supply of options, potentially reducing short‑term dilution risk.
Analyst upgrade to outperform with a high price target suggests upside potential.
Governance change with modest compensation impact; unlikely to move price materially.
Enrollment completion de-risks trial execution and sets expectations for topline MIST data in 2H 2027, supporting a longer-dated catalyst path.
AlphAI scores every news story that mentions AVLN with an AI model for sentiment and relevance, and aggregates insider trades from Avalyn Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers Presented new AP01 data at ERS Congress and published detailed results from
Avalyn Pharma Inc. stock options are locked up until 27-OCT-2026. Directors, officers, and major holders agreed not to sell or transfer shares for 180 days post-prospectus. The company focuses on inhaled therapies for pulmonary fibrosis, with clinical trials ongoing for AP01, AP02, and AP03.
Raymond James initiated coverage on Avalyn Pharma (NASDAQ:AVLN) with an outperform rating and a $60 price target, implying over 118% upside. The company is developing inhaled antifibrotics for pulmonary fibrosis, with two Phase 2 assets. Avalyn's market cap is $1.22B, and it has a strong balance sheet. Raymond James expects catalysts in late 2027, while InvestingPro suggests the stock may be overvalued.
Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corpora
Avalyn Pharma (AVLN) reported Q2 2026 results and said enrollment is complete for the global Phase 2b MIST trial of inhaled AP01 (pirfenidone) in progressive pulmonary fibrosis. The randomized, double-blind study enrolled 398 patients vs a 375 target, with 52-week safety and efficacy and topline data expected in H2 2027. Q2 R&D was $24.7M, net loss $28.9M, and cash $413.5M.
Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory S
Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ck0001540171-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (this “ Amendment ”) is made and entered into as of June 29, 2026 (the “ Effective Date ”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation
